GTC
CRBP icon

Ghost Tree Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Ghost Tree Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.54M Buy
+220,000
New +$11.3M 1.37% 27

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ghost Tree Capital's CRBP Position: Q3 2024 in Review

Ghost Tree Capital reduced its Corbus Pharmaceuticals (CRBP) stake by 8.6% in Q3 2024, selling an estimated $768K and leaving 160,000 shares worth $3.3M. The position accounts for 1% of the portfolio, ranked #36.

Ghost Tree Capital first reported a position in CRBP in Q2 2016 and has held it in 5 quarters since. The position peaked at $7.92M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Ghost Tree Capital held 160,000 shares of Corbus Pharmaceuticals worth $3.3M as of Q3 2024.
  • Ghost Tree Capital sold 15,000 Corbus Pharmaceuticals shares in Q3 2024, an estimated $768K.
  • Corbus Pharmaceuticals made up 1% of Ghost Tree Capital's portfolio in Q3 2024, its #36 holding.
  • Ghost Tree Capital first reported a position in Corbus Pharmaceuticals in Q2 2016 and has held it in 5 quarters since.
  • Ghost Tree Capital's Corbus Pharmaceuticals position peaked at $7.92M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.